Adrian Woolfson
Directeur/Membre du Conseil chez ImmunoSCAPE Pte Ltd.
Profil
Adrian Woolfson is currently the Director at ImmunoSCAPE Pte Ltd.
He previously worked as the Head-Global Clinical at Pfizer Inc. from 2015 to 2018, as the Executive Vice President-Research & Development at Sangamo Therapeutics, Inc. from 2019 to 2020, and as the Chief Medical Officer at Nouscom AG in 2018.
Dr. Woolfson received his undergraduate degree from the University of Oxford in 1995 and his doctorate degree from the University of Cambridge in 1992.
Postes actifs de Adrian Woolfson
| Sociétés | Poste | Début |
|---|---|---|
ImmunoSCAPE Pte Ltd.
 ImmunoSCAPE Pte Ltd. BiotechnologyHealth Technology ImmunoSCAPE Pte Ltd. develops immunotherapy and leveraging therapies. The firm focuses on immunotherapy and leveraging a unique high-dimensional immune profiling Platform. The company was founded by Choon-Peng Ng, Alessandra Nardin, Michael Fehlings and Evan Newell in 2016 and is headquartered in Singapore. | Directeur/Membre du Conseil | 28/07/2021 |
Anciens postes connus de Adrian Woolfson
| Sociétés | Poste | Fin |
|---|---|---|
| SANGAMO THERAPEUTICS, INC. | Directeur Technique/Scientifique/R&D | 24/06/2020 |
Nouscom AG
 Nouscom AG Pharmaceuticals: MajorHealth Technology Nouscom AG engages in the development of genetic neoantigen vaccines and oncolytic viruses for prevention and treatment of cancer. Its product pipeline include Nous-209, Nous-PEV, and Nous-THV-001. The company was founded by Alfredo Nicosia, Antonella Folgori, Riccardo Cortese, Stefano Colloca, Cinzia Traboni, Elisa Scarselli, and Gabriella Campadelli in 2007 and is headquartered in Basel, Switzerland. | Directeur Technique/Scientifique/R&D | 01/11/2018 |
| PFIZER, INC. | Directeur Technique/Scientifique/R&D | 01/01/2018 |
Formation de Adrian Woolfson
| University of Oxford | Undergraduate Degree |
| University of Cambridge | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| SANGAMO THERAPEUTICS, INC. | Health Technology |
| PFIZER, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Nouscom AG
Nouscom AG Pharmaceuticals: MajorHealth Technology Nouscom AG engages in the development of genetic neoantigen vaccines and oncolytic viruses for prevention and treatment of cancer. Its product pipeline include Nous-209, Nous-PEV, and Nous-THV-001. The company was founded by Alfredo Nicosia, Antonella Folgori, Riccardo Cortese, Stefano Colloca, Cinzia Traboni, Elisa Scarselli, and Gabriella Campadelli in 2007 and is headquartered in Basel, Switzerland. | Health Technology |
ImmunoSCAPE Pte Ltd.
ImmunoSCAPE Pte Ltd. BiotechnologyHealth Technology ImmunoSCAPE Pte Ltd. develops immunotherapy and leveraging therapies. The firm focuses on immunotherapy and leveraging a unique high-dimensional immune profiling Platform. The company was founded by Choon-Peng Ng, Alessandra Nardin, Michael Fehlings and Evan Newell in 2016 and is headquartered in Singapore. | Health Technology |
